Lupin surges 10% on good volumes after getting EIR from USFDA for Goa plant

Despite of today's gain, the stock has underperformed the market by falling 18 per cent in past six months, as compared to 10.5 per cent rally in the S&P BSE Sensex

Shares of Lupin surged 10 per cent to Rs 972.50 on the BSE in Tuesday’s intra-day trade, after the drug-maker announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility. The US drug regulator had inspected the facility in September 2021.

Lupin said the US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

“This is a significant milestone as we build back our reputation of being best-in-class in Quality and Compliance. We are committed to manufacture and